The intravenous pentylenetetrazol (i.v.PTZ) seizure test provides threshold dose for induction of seizures in individual animals. In the present study, the i.v. and s.c.PTZ seizure models in mice were compared for seizure pattern, intra-and interanimal variability. Anticonvulsant activities of several antiepileptic drugs (AEDs) at non-ataxic dose levels were evaluated in the PTZ and maximal electroshock (MES) seizure tests. In the i.v.PTZ test, at 0.5 ml/min rate of administration, the mean threshold PTZ doses for induction of clonus and tonic extensor were 44.17 and 99.59 mg/kg, respectively. The intra-and interanimal variabilities in the seizure response were low in the i.v.PTZ as compared to the s.c.PTZ model. Phenobarbital sodium, ethosuximide, sodium valproate, diazepam, tiagabine, oxcarbazepine and zonisamide enhanced threshold or onset latency for clonus in the i.v. and s.c.PTZ tests, respectively. Levetiracetam and pregabalin were active in the i.v.PTZ test, but had no effect in the s.c.PTZ test. Ability of AEDs to protect from tonic extensor was compared in the MES and i.v.PTZ tests. For this effect, phenobarbital sodium, phenytoin, carbamazepine, sodium valproate, gabapentin, oxcarbazepine, zonisamide and pregabalin were effective in the i.v.PTZ and MES tests. Ethosuximide, diazepam and levetiracetam were effective in the i.v.PTZ test, but not the MES test. On the contrary, lamotrigine and topiramate were active in the MES, but not the i.v.PTZ test. These results indicate that it is advantageous to use i.v.PTZ test as an acute seizure model for screening of antiepileptic drugs. This model can identify molecules with varied mechanism of action and broad clinical utility in the treatment of epilepsy.
Introduction
Animal seizure models have played a significant role in epilepsy research including identification and characterization of new antiepileptic drugs (AEDs). 1 Recent years have witnessed a significant progress towards uncovering the cellular and molecular mechanisms of epilepsy. This has provided impetus to the target-based drug design and mechanismoriented approach for the identification of new AEDs. However, the current understanding of molecular biology of epilepsy is still too limited to employ in vitro screening as the only tool in the search for new AEDs. Consequently, animal models continue to form useful component of a panel of screening tests for AED identification. 2 There remains a need for reliable animal models which are easy to use and which allow assessment of drug's ability not only to suppress the seizures but also to prevent development of epilepsy (epileptogenesis). 3 Two most extensively studied and well established animal seizure models are MES, maximal electroshock-induced seizures in mice and s.c.PTZ, subcutaneous pentylenetetrazol-induced seizures in mice. 4 Both tests provide models of single, acute seizures. The MES test identifies compounds which prevent seizure spread, whereas the s.c.PTZ test identifies compounds which primarily raise seizure threshold. 5, 6 Depending on dosage, PTZ can produce myoclonic jerking movements, clonic convulsions, or forelimbs/hindlimbs tonic extensor (TE). With some minor exceptions, the pharmacological profile of the s.c.PTZ seizure model is consistent with the human condition. 7, 8 It can be reasonably accepted that screening by the s.c.PTZ test identifies those compounds which enhance GABAergic neurotransmission or which act by affecting T-type calcium (Ca 2+ ) channels. 9 Phenobarbital, vigabatrin and tiagabine which work through GABAergic mechanisms and ethosuximide which work through T-type Ca 2+ channels, suppress s.c.PTZ-induced seizures in animals. 5, 10 Usually, seizures are induced by a single fixed dose of PTZ and the onset latency/severity/duration of seizure response is monitored. The calculation of threshold PTZ dose to induce seizures using the fixed dose method would require dose-response data generated by giving various doses of s.c.PTZ to different groups of animal. This would necessitate the use of relatively large number of animals.
An intravenous PTZ (i.v.PTZ) infusion with a constant flow rate through the tail vein in mice 11, 12 or the jugular vein catheter in rats 13 elicits seizure response in a reliable, reproducible and rapid manner. AEDs can elevate seizure threshold 13, 14 or modulate electrographic seizure activity 15 
Methods Animals
Male CD-1 mice, bred in the animal facility of Sun Pharma Advanced Research Centre (SPARC), Baroda; age 5-6 weeks, weighing 25-30 g were used. They were housed in a group of six animals/cage in polypropylene cages, at constant temperature of 22 AE 2 8C and relative humidity of 60-70%, air changes >12 h À1 , with automatically controlled 12/12 h light/dark cycle, lights on at 7.00 h. All animals were provided with the pelleted standard diet (Harlan Teklad Global Diet, UK) and drinking water in water bottles. Experiments were conducted during the light phase between 9.00 a.m. and 4.00 p.m. Each animal was naïve. All the experiments were performed in accordance with the guidelines of the Institutional Animal Ethics Committee (IAEC) of SPARC. Animals surviving after completion of the study were sent for their disposal under the IAEC approved protocol.
Drugs and reagents
Pentylenetetrazol and ethosuximide was purchased from Sigma Chemicals Co. St Louis, MO. The following drugs were obtained from various sources as indicated: diazepam, carbamazepine, sodium valproate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, zonisamide and pregabalin (Sun Pharmaceutical Industries Ltd., Baroda, India), phenobarbital sodium (Marketed product, Nicholas Ltd., Mumbai, India) and phenytoin (J.P. Pharmachem, Thane, India).
Drug administration
All drugs and PTZ solutions were made freshly before administration. PTZ was dissolved in heparinized sterile 0.9% saline to prepare 10 mg/ml concentration for i.v. administration. For s.c. administration, it was dissolved in 0.9% saline to prepare 8.5 mg/ml concentration. Gabapentin, sodium valproate, phenobarbital sodium, levetiracetam and ethosuximide were dissolved in water. All other drugs were suspended in 0.5% carboxymethyl cellulose sodium (CMC). Before drug administrations, animals were deprived of food for 5 h keeping water available ad libitum. The drugs were administered by per oral route, 60 min before administration of PTZ using oral gavage in a volume of 0.01 ml/g body weight. Administration of water or 0.5% CMC had no effect on the seizures induced PTZ or MES, hence all vehicle control animals received water even when the vehicle for a drug was 0.5% CMC. Table 3 shows the doses of different drugs used in this study. Selection of doses were based on literature reports and the preliminary experiments conducted in our labs, such that the selected dose of a drug, except levetiracetam and gabapentin, would cause suppression of seizures in either the MES or s.c.PTZ test without producing apparent motor toxicity (ataxia). Since levetiracetam and gabapentin were ineffective in both the s.c.PTZ and MES tests, doses of these drugs were based on their efficacy in the i.v.PTZ test. The t max (and the time to maximal response) for different AEDs differ. However, the doses used in this study were large enough to presumably give effective brain levels at 1 h of their administrations.
Timed intravenous pentylenetetrazol infusion test
The test was conducted in mice with some modification in the previously reported method. 12 A butterfly cannula (needle size 27 G, 3/4 in., Top Infusion Set, Meditop Corporation, Malaysia) attached to a 5 ml syringe prefilled with heparinized PTZ solution was used. For the purpose of infusion, the animal was restrained and needle was inserted into the tail vein. The accuracy of needle placement in the vein was confirmed by appearance of blood in the cannula. The needle was secured to the tail by a special tape. The animal was kept in a transparent Perspex box with holes for ventilation. The syringe was held in the adjustable motor driven infusion pump (KDS Syringe Pump, USA). In this way animal could move freely in the box without strain on the attached cannula with no severe struggling. Few animals required readjustment of needle. PTZ was infused at a constant rate of 0.5 ml/min. During the infusion, mice were observed for the onset of different types of seizures by a trained and treatment blind observer. The time latencies from start of infusion to the appearance of first clonus (characterized by the rapid involuntary rhythmic contraction and relaxation of limbs), lasting longer than 5 s and subsequent tonic forelimb and/or hindlimb extension (characterized by stretching of limbs) was recorded. Infusion was stopped at the appearance of TE in each animal. The threshold doses in mg/kg for appearance of clonic and tonic seizures were calculated using the following formula: rate of infusion ðml=minÞ Â time for onset of seizure ðsÞ Â concentration of PTZ ðmg=mlÞ Â 1000 60 Â body weight of animal ðgÞ
The infusion of PTZ was terminated at 1 min, in case of non-appearance of TE. For such animals, the dose of PTZ in mg/kg infused till 1 min was calculated as the threshold dose.
Subcutaneous pentylenetetrazol seizure test
Mice were administered 85 mg/kg dose of PTZ subcutaneously into a loose fold of skin of the neck, between two shoulder blades. Animals were observed over the course of 60 min for appearance of clonus and TE. Animals not displaying seizures during this period were assigned an arbitrary cut-off time latency of 30 min for the calculations of mean onset latency for clonus. 16 In the experiments designed to determine intraand interindividual variability in the i.v. and s.c.PTZ-induced seizure responses, PTZ administrations were done at an interval of 48 h.
Maximal electroshock seizure
A drop of saline solution (0.9% saline) was placed in each eye of mice. The corneal electroshock stimulus (rectangular positive pulses of 50 mA at 60 Hz for 0.2 s duration, ECT Unit, Ugo Basile, Comerio, Italy) was delivered as described in the previously reported methods. 16, 17 The percentage of animals showing abolition of the hind limb TE was calculated.
Data analysis
The mean threshold dose or time latency to seizure responses for each group were calculated from the individual values of six animals and compared with their respective vehicle control group by one-way ANOVA followed by Dunnett's test. The percent incidence of TE in the MES test was calculated from the number of animals showing these effects in each treatment group and compared with the vehicle control group by the Chi-square or Fisher exact test, depending upon sample size. Significance was considered as p < 0.05, versus the vehicle group.
Results
An intravenous infusion of PTZ with a constant flow rate in mice elicited stereotyped seizure response in the following sequence: vibrissal/jaw twitching, myoclonic jerking with vocalization, repeated forelimb clonus, jerking of whole body followed by forelimb/hindlimb clonus and forelimb/hindlimb TE. The seizure manifestation progressed from one stage to the other, as the infusion progressed. It was possible to limit the seizure activity by controlling the infusion. The seizures progressed only to a modestly higher level after terminating the infusion. The concentration of PTZ solution and its rate of infusion were constant. Therefore, body weight of animal and time duration of infusion were the only variables required to be used in the calculation of threshold dose for an individual animal (Table 1) . When infusion terminated at the occurrence of clonus, the animal behaviors returned to their normal within 1-1.5 h with grooming seen comparable to the vehicle control animals. The mean control threshold PTZ dose for onset of clonus was 44.17 mg/kg and for onset of TE it was 99.59 mg/ kg (Table 3) . Interindividual variation in the threshold dose for induction of clonus was low with the mean interindividual coefficient of variation of 8.24% (Table 2) .
s.c.PTZ-induced seizure response progressed from one stage to another as that of i.v.PTZ, albeit with a different time course and behavioral manifestation. Clonic seizures were followed by locomotor depression with some animals also displaying cataleptic postures or jumping. The elaborate pattern of behavioral responses can be described as: vibrissal twitching, myoclonic jerking with vocalization and Straub's tail, loss of righting and regaining Timed pentylenetetrazol infusion test within few seconds, freezing/suppression of locomotion, cataleptic posture, tremors, increased breathing, jumping and/or vocalization in some animals, forelimb/hindlimb clonus, hindlimb TE. A seizure was preceded by an increase in the locomotion/exploration and was followed by a suppression of locomotion (Table 1) . Suppression of motor activity was still evident at 2 h of s.c.PTZ administration. At PTZ dose of 85 mg/kg, s.c.-used in this studywhich is most commonly used dose for induction of clonus, 8 the mean interindividual coefficient of variation was 33.18% (Table 2 ). About 30% of the animals administered with s.c.PTZ also exhibited TE. Large variability in the onset latency of TE was observed in these animals (13.5-20.3 min).
To determine reproducibility of seizure response in the same animal, the test was conducted twice in the same group of animals with 48 h duration between two tests. The threshold for onset of clonus in an individual animal varied less in the i.v.PTZ test (the mean intraindividual coefficient of variation 7.64%), as compared to the time latency for onset of clonus in its s.c. counterpart (the mean intraindividual coefficient of variation 26.65%). These results are presented in Table 2 .
All animals applied with maximal electroshock produced TE followed by a brief clonus.
Presently marketed 14 AEDs were assessed in the PTZ and MES models. The same dose of a particular drug was used in all the three models (Table 3 ). All AEDs were administered 60 min prior to the test. Therefore, anticonvulsant effects seen may not be the peak effect of a particular drug.
Phenobarbital Na, sodium valproate, ethosuximide, diazepam, tiagabine, oxcarbazepine and zonisamide showed protection from clonic seizures in the i.v. as well as s.c.PTZ tests. Levetiracetam and pregabalin were active in the i.v.PTZ test. In the s.c.PTZ test, these drugs did not cause significant reduction of clonic seizures compared to vehicle treatment. Phenytoin, carbamazepine, lamotrigine and topiramate, which exert Na + channel inhibitory effects and gabapentin had no effect on appearance of clonus in both the s.c. and i.v.PTZ tests. It was observed that the vocalization during myoclonic jerking was prevented by gabapentin treatment. In general, suppression of clonic seizures by different AEDs correlated well between the i.v. and s.c.PTZ tests. However, more precise comparison may require calculation of ED 50 values of AEDs in these seizure models.
AEDs effective against TE in the i.v.PTZ and MES tests were--phenobarbital sodium, phenytoin, carbamazepine, sodium valproate, gabapentin, tiagabine, oxcarbazepine, zonisamide and pregabalin. Ethosuximide, diazepam and levetiracetam caused reduction of TE induced by i.v.PTZ, but not by the MES. On the other hand, the protective effect of lamotrigine and topiramate were significant only in the MES test, but not in the i.v.PTZ test. In the i.v.PTZ model, topiramate and oxcarbazepine treated animals presented with only forelimb TE. The hindlimb TE was completely abolished by these drugs, in contrast to forelimb/hindlimb TE noted in control animals.
In summary, except levetiracetam all other AEDs showed protective effect in either or both the s.c.PTZ and MES tests. On the other hand, except lamotrigine and topiramate, all other AEDs showed protective effect in the i.v.PTZ test. Levetiracetam caused an increase in the threshold for clonus as well as TE and gabapentin caused an increase in the threshold for TE in the i.v.PTZ test.
Discussion
Seizure model using subcutaneous administration of PTZ has been used widely for preclinical evaluation of anticonvulsant properties of new drugs. 4 The usefulness of this model in AED screening programs has been debated recently. 18 In laboratory animals, PTZ administration induces a continuum of behavioral response starting from small myoclonic twitches, clonic seizures and threshold tonic extensor or supramaximal tonic extensor. 19 The onset and intensity of occurrence of seizures depends on the dose of PTZ.
In this study, all animals administered with 85 mg/kg, s.c.PTZ showed clonus. However, the interanimal variability in the onset of clonus was large as compared to the i.v.PTZ model. The onset of clonus has been shown to be associated with the brain concentration of PTZ. Earlier studies determining brain concentrations of PTZ at the onset of clonus indicate that the specific threshold concentration of PTZ in the brain is required to induce convulsions in mice 20 or rat. 21 Different studies have reported that quite similar brain levels of PTZ are required to induce seizures when PTZ is administered by different routes. However, the time of onset of myoclonus and clonus depends upon time required to attain the threshold brain concentration of PTZ. 21 Therefore, interanimal variability in the time to achieve threshold PTZ concentration might lead to interanimal variability in the onset of seizures. On subcutaneous administration, the brain uptake of PTZ has been reported to be gradual, 20 perhaps reflecting gradual absorption of PTZ from the site of injection. The absorption phase is avoided during i.v. administration which could explain the low interanimal variability in the onset of clonus. However, a large degree of variability in the onset of TE cannot be explained simply by considering pharmacokinetic (PK) factors in the effects of PTZ. In the PTZ model, occurrence of TE is always preceded by myoclonus, clonus and a period of depression (postictal depression). The onset of TE is believed to be influenced by these behaviors in addition to the PK of PTZ. In mice with rapidly arising brain PTZ levels, overt behavioral manifestations of seizures are delayed for the length of postictal depression, during which the CNS remains refractory to further seizure activity. If the brain PTZ level is supramaximal for the TE at the end of the postictal depression, the animal will have a TE seizure. 20 The brain PTZ levels can be expected to rise more uniformly and rapidly on its i.v. infusion. This would lead to a less variation in the onset of TE. In fact, as indicated in Table 1 , in the i.v.PTZ model, postictal depression is almost masked, presumably due to a rapidly rising brain PTZ levels; hence it might have negligible effect on the onset of TE. Piredda et al. noted that it was impossible to induce supramaximal seizures with s.c.PTZ in 97% of mice with s.c. administration of PTZ, in contrast to i.v.PTZ. 5 The onset of TE is not the commonly considered endpoint in the anticonvulsant screening using the s.c.PTZ model. 20 However, it should be noted that PTZ-induced TE ensue a high mortality in animals.
In i.v.PTZ treated mice, when infusion is terminated at the appearance of clonus, the behavior returned to baseline earlier compared to s.c.PTZ treated mice. In fact, the total dose of PTZ administered to induce forelimb/hindlimb clonus is quite less in the i.v.PTZ model (45 mg/kg) than in the s.c.PTZ model (85 mg/kg).
Intraanimal variability was low in the i.v.PTZ model as compared to the s.c.PTZ model. In order to rule out the pharmacokinetic component, the time duration of 48 h was kept between two doses of PTZ (half-life of PTZ by s.c.route is reported to be 3.5 h). The mechanism by which PTZ induces convulsions is still unclear; its pharmacological effects are at least partly mediated by interaction with the chloride ion channel of the GABA A receptor. 22, 23 Conversely, acute tonic-clonic seizures induced by PTZ or electroshock alter GABA A receptors number or function. 24 At 45 mg/kg dose of PTZ, Walsh et al. reported that transient reduction in GABA A receptor mRNA takes place in hippocampus, cerebral cortex and cerebellum which reverts to control levels by 48 h. 24 However, the changes in the GABA receptor number or function cannot be entirely ruled out when given at a dose of 85 mg/kg, subcutaneously. In all probabilities, the decrease in GABA A receptor mRNA seen after PTZ, if maintained long enough could lead to decrease in number of GABA A receptor and GABAergic inhibition. 24 Primarily different protocols are followed in the i.v.PTZ and s.c.PTZ test leading to different time course and the amount of PTZ delivered to the brain. Hence, further work to elucidate the mechanism of differential intraanimal variability in the i.v. and s.c.PTZ models is required. The notable advantage of low intraanimal variability in the i.v.PTZ test is that AED evaluation using this model can be performed in a longitudinal way. Thus, each animal can serve as its own control. A study following such an experimental design exists in the literature. 13 Proposed mechanisms of action of AEDs used in this study are listed in Table 3 . In the present study, drugs potentiating GABAergic neurotransmission, i.e. phenobarbital, diazepam and tiagabine were effective in both the i.v. and s.c.PTZ tests. Sodium valproate appears to cause blockade of voltagesensitive Na + channels, 25 T-type Ca 2+ channels 26 and elevates whole-brain GABA levels 27 was able to enhance the threshold for seizures in the i.v.PTZ model, although its effect in s.c.PTZ model was not significant. The drugs with T-type Ca 2+ channel blockade as one of their effects, i.e. ethosuximide and zonisamide were also effective in both the PTZ tests. Certainly, zonisamide has other effects including inhibition of glutamate-induced excitation and enhancement of dopaminergic/serotonergic neurotransmission. 28 Oxcarbazepine, a Na + and Ltype Ca 2+ channel blocker also caused significant inhibition of clonic seizures in both the PTZ tests. Oxcarbazepine has been shown to reduce PTZinduced seizures. 29 Literature reports are inconsistent with respect to anticonvulsant action of zonisamide in the s.c.PTZ model. 27 Both zonisamide and oxcarbazepine have clinical utility in the treatment of generalized tonic-clonic and partial seizures. 30 Zonisamide also works in absence and myoclonic convulsions. 28 These results reinforce the view that, contrary to previous notion, the utility of s.c.PTZ model (and of the i.v.PTZ model) is not limited to identification of AEDs effective in absence seizures. 18 The potential molecules with broad spectrum of anticonvulsant activity can be selected by screening in the PTZ test.
Levetiracetam was uniquely effective in the i.v.PTZ model. Levetiracetam has been shown to exhibit antiepileptogenic effect in developing and fully developed seizures in the kindling model of epilepsy in rat. 31 Levetiracetam possess binding at SV2A, a synaptic vesicle protein. 32 In the present study, higher doses were required to produce suppression of clonus and TE compared to the dose that has been reported for inhibition of seizures in the kindling model. There is evidence to show that levetiracetam, at least in part, work through potentiation of GABAergic impairment. 33 Impairment of GABAergic mechanism has been thought to play a crucial role in the processes underlying epileptogenesis in the kindling model. 34 Valproate Na and phenobarbital which affect GABAergic transmission at sedative/ataxic doses appear to be antiepileptogenic in kindling models. 35 These evidences together with anticonvulsant activity of drugs enhancing GABAergic inhibition in the PTZ seizure model indicate that the i.v.PTZ model may have utility not only in identifying antiseizure agents but also antiepileptogenic agents. However, more studies to compare the effects in the i.v.PTZ model with kindling model are required.
The distinctive effects of i.v. and s.c.PTZ administrations in the seizure expression and differential efficacy of AEDs in these two models suggest distinct mechanisms for mediation of seizure activity in these models. The difference in the rate and extent of delivery of PTZ to the brain may lead to differential pattern of activation of neuroanatomical substrates that are involved in the mediation of PTZ seizures. The studies by Keogh et al. using the functional magnetic resonance imaging of PTZinduced seizures in rats showed that seizure initiation in the i.v. and i.p.PTZ models involve multiple regions of sensitivity that vary with the route of administration. 36 Intravenous administration of PTZ produces single dominant cluster, whereas its intraperitoneal administration produces a multiple, relatively small clusters with heterogenous time course that vary across the animals. 36 The likelihood of altered brain kinetics of AEDs due to difference in the i.v. and s.c.PTZ delivery cannot be ruled out. Also, disruption or breakdown of the blood-brain barrier due to acute seizure activity can affect the anticonvulsant activity of compound. 37 The MES test is considered as an appropriate model of generalized tonic-clonic seizures. Differential pattern of seizure phenomenology and effectiveness of anticonvulsant agents in the PTZ and MES models was seen in this study. Miller et al studied the difference in the neuronal pathways involved in the MES and PTZ-induced seizures. 37 PTZ-induced seizures appear to be mediated by an extensive system involving the reticulate formation, diencephalic region and caudal hypothalamus. In contrast, substantia nigra is the only definite structure found to be involved in the MES seizures. 38 The Na + channel blocker AEDs-phenytoin, carbamazepine, oxcarbazepine and also the drugs with multiple mechanisms, including Na + channel blockade as one of their effect, i.e. phenobarbital and sodium valproate caused suppression of i.v.PTZ as well as MES-induced TE. In the i.v.PTZ model, topiramate did not cause significant increase in the threshold for seizures. Topiramate has been shown to have weak effect at 175 and 200 mg/kg dose in raising threshold of clonus in the s.c.PTZ model. 38 Diazepam at 1 mg/ kg dose was not effective in the MES model. At 5 mg/ kg dose, diazepam caused complete suppression of MES-induced TE (data not shown). However, these doses of topiramate and diazepam induce potent ataxia in animals.
Gabapentin and levetiracetam showed protective effect in i.v.PTZ induced TE. Levetracetam's effect has been discussed in foregoing discussion. Gabapentin has no known effect at Na + channels. By far, the binding to the a 2 d subunit of voltage activated Ca 2+ channels is the only convincing mechanism of antiepileptic effect of gabapentin. 39 Pregabalin is follow-up compound of gabapentin with similar proposed mechanism. 40 In summary, the i.v.PTZ test has ability to screen molecules with varied mechanism of action and clinical utility in the treatment of epilepsy. In addition to being sensitive model, it also allows to determine the effect of drugs on separate components of seizure behavior. Additionally, the i.v.PTZ test has known utility for evaluation of proconvulsant potential of a compound. 41 This is an important consideration because several of the newly introduced AEDs are being reported to exacerbate or induce de novo absence and/or myoclonic attacks in patients.
